drugset / Trial / NCT02370706
Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis
NaParallel-groupOpen-labelHealth-services research
Summary
This is a phase Ib study with the primary purpose is to estimate the MTD and/or RDE for the triple combination of PIM447, formerly LGH447, plus ruxolitinib and LEE011 as well as for the doublets, PIM447 plus ruxolitinib, and LEE011 plus ruxolitinib, in patients with myelofibrosis (MF). Each regimen will be assessed for safety, tolerability, pharmacokinetics (PK) and pharmacodynamic effects, and preliminary anti-myelofibrosis activity, including changes in spleen volume, JAK2V617F allele burden, and hematologic response.
Timeline
- Start
- 2015-05-21
- Primary completion
- 2020-11-09
- Completion
- 2020-11-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LGH447 | Small molecule | — | Oral |
| Subject | Ribociclib | Small molecule | — | Oral |
| Subject | Ruxolitinib | Small molecule | — | Oral |